MedPath

ew laser treatment of MTM study

Phase 2
Conditions
myopic traction maculopathy
Registration Number
JPRN-jRCTs032190239
Lead Sponsor
Ohno-Matsui Kyoko
Brief Summary

Five myopic traction maculopathy patients with decreased vision were enrolled and received Nd:YAG laser internal limiting membrane ablation at the peripheral macular area. There was no unpredictable adverse event. There was no significant change of retinal thickness both at the fovea and at the point of laser treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
5
Inclusion Criteria

1) Myopic traction maculopathy with ocular axial length of more than 26.5 mm
2) Decreased visual acuity caused by myopic traction maculopathy which diagnosed by two ophthalomologists who are specialized in myopia
3) Age of more than 20 years old
4) Written informed consent
5) Judged as an appropriate study participant by two ophthalomologists who are specialized in myopia

Exclusion Criteria

1) Pupil diameter of less than 3 mm with mydriatic examination
2) Opacity of cornea, lens, or vitreous which prevent image examination of ocular fundi.
3) Severe cardiopulmonary disease
4) Disability to keep sitting position
5) Judged as an inappropriate study participant by two ophthalomologists who are specialized in myopia

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Retinal thickness at treated cite 6 months after treatment
Secondary Outcome Measures
NameTimeMethod
Central retinal thickness at treated cites and visual acuity at 6 months after treatment
© Copyright 2025. All Rights Reserved by MedPath